Pharmaceutical Technology

FEBRUARY 24, 2023

Amivantamab overview Amivantamab-vmjw (Rybrevant) is a low-fucose human immunoglobulin G1-based bispecific antibody developed using recombinant DNA technology. It is based on DuoBody technology platform. It is formulated as solution and concentrate for solution for intravenous infusion.

Recombinant DNA Technology 100

Recombinant DNA Technology Production Antibody FDA Approval 100

Pharmaceutical Technology

FEBRUARY 15, 2023

Innovation S-curve for the pharmaceutical industry Gene splicing using nucleases is a key innovation area in the pharmaceutical industry Nucleases play a fundamental role in the field of recombinant DNA technology, or genetic engineering. Nucleases are enzymes that hydrolytically cleave the phosphodiester backbone of DNA.

Gene Splicing 130

Gene Splicing Gene DNA Recombinant DNA Technology 130

Roots Analysis

JANUARY 21, 2024

Conventional conjugation technologies used for the development of ADCs exploited the superficial lysine residues that were inherent to the native antibody structure, or the inter-chain cysteine residues, for drug-linker attachment.

Antibody 40

Antibody Recombinant DNA Technology Drugs Marketing 40

Cloudbyz

MARCH 6, 2024

Unlike traditional small molecule drugs, which are chemically synthesized, biologics are produced through complex biotechnological processes, often involving recombinant DNA technology. Understanding Biologics: Biologics are a class of therapeutic agents derived from living organisms, such as cells, tissues, or proteins.

Gene 99

Gene Immune Response Manufacturing Gene Therapy 99

Advarra

JUNE 13, 2024

Recombinant DNA technologies and genetically modified biological agents are being adapted for a wide scope of therapeutic applications, and their use is becoming increasingly common in clinical trials. These IPs pose the lowest risk amongst all recombinant IPs.

Genetic Engineering 52

Genetic Engineering Clinical Trials Clinical Trials Engineer 52

The Pharma Data

JULY 11, 2021

Hereditary angioedema is a lifelong condition and research shows that concerns about another attack can limit the way patients lead their lives,” said Prof. TAKHZYRO is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. percent (-100; 852.8), and the median reduction was 97.7 Markus Magerl, M.D.,

Allergies 52

Allergies Antibody Recombinant DNA Technology Production 52